Somnomed Ltd
ASX:SOM
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
AU |
Somnomed Ltd
ASX:SOM
|
23.3m AUD | -1.5 | ||
US |
Abbott Laboratories
NYSE:ABT
|
182B USD | 77 | ||
US |
Intuitive Surgical Inc
NASDAQ:ISRG
|
135.7B USD | 227.8 | ||
US |
Stryker Corp
NYSE:SYK
|
123.6B USD | 46.1 | ||
IE |
Medtronic PLC
NYSE:MDT
|
111.3B USD | 80.1 | ||
US |
Boston Scientific Corp
NYSE:BSX
|
107.1B USD | 32.3 | ||
US |
Becton Dickinson and Co
NYSE:BDX
|
68.4B USD | 32.7 | ||
DE |
Siemens Healthineers AG
XETRA:SHL
|
58.9B EUR | 69.1 | ||
CN |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
371.2B CNY | 37.1 | ||
US |
Edwards Lifesciences Corp
NYSE:EW
|
51.1B USD | 83.5 | ||
US |
Dexcom Inc
NASDAQ:DXCM
|
49.5B USD | 84.9 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.